Tech Company Financing Transactions
Totient Funding Round
Private investors participated in a $10 million Seed capital raise for Totient. The round was announced on 9/14/2020.
Transaction Overview
Company Name
Announced On
9/14/2020
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Seed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Alewife Center 120
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Website
Email Address
Overview
Totient is an AI-driven biotechnology company leveraging tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. Totient reconstructs antibodies from tissues affected by autoimmunity, infections, and cancer collected from patients experiencing exceptional immune responses.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Deniz Kural
Vice President
Daniele Biasci
VP - Bus. Development
James Sietstra
Browse more venture capital transactions:
Prev: 9/14/2020: Replicant venture capital transaction
Next: 9/14/2020: Squadle venture capital transaction
Share this article
News on VC Transactions
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs